Chris Stijnen

Chief Commercial Officer (CCO)

Chris Stijnen joined Relief in December 2020 as its Chief Commercial Officer. He is a highly experienced pharmaceutical executive with a successful track record in marketing, general management, access strategy and product development across a variety of indications. Prior to joining Relief, he had an impressive career with Bristol-Myers Squibb, where he was responsible for the marketing and commercialization of the company’s portfolio in various international subsidiaries between 2005 and March 2020. Most recently he was VP Product & Portfolio Strategy and Interim Head Commercial Strategy and Capabilities for Bristol-Myers Squibb China in Shanghai, China. Before that, he was Head Operations & Japan liaison, Product Portfolio and Access Strategy Department for Bristol-Myers Squibb Worldwide Commercial Organization in Princeton, New Jersey, USA. Prior to this, he developed early access strategies for specialty and orphan pipeline drugs as Access Strategy Lead Immunology, Fibrosis & Genetically Defined Diseases. Chris accumulated further product launch and commercialization experience as General Manager and President Director at Bristol-Myers Squibb locations in Russia, Turkey and Indonesia. His career with Bristol-Myers Squibb followed a 15-year tenure with Organon, which was acquired in 2007 by Schering-Plough Corporation (now part of Merck & Co.). At Organon, he held positions in local and global Marketing, Area Management Latin America, and served as General Manager Organon Vietnam.

A native of The Netherlands, Chris earned a MSc. in Business Economics from Erasmus University Rotterdam.